Fascination About Tyrosinase-IN-12
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage numerous intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major demo objectives ended up To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis suf